- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06244602
Test-retest and Experiences During Balance Assessment With the Mini-BESTest
Balance Assessment in Individuals With Chronic Pain: an Explorative Study of Psychometric Properties of the Mini-BESTest
The goal of this observational study is to test psychometric properties of a clinical balance assessment scale, the Mini-BESTest, as well as to explore experiences and beliefs about balance and being balance tested. The main research questions are:
- What is the test-retest reliability of the Mini-BESTest balance assessment scale for individuals with long-term pain?
- What is the individual's subjective beliefs and experiences about their own balance and being balance tested with the Mini-BESTest?
Tow samples of participants will be included. One sample for a) the test-retest evaluation or b) an interview during and after performing the Mini-BESTest.
Study Overview
Status
Conditions
Detailed Description
Individuals with chronic pain, i.e., pain > 3 months, report balance problems and falls in their everyday lives. How balance affects daily functioning, and how to identify individuals with balance impairments are less studied. The Mini-BESTest has previously shown adequate construct validity in individuals with chronic pain, however, the test-retest reliability has not been explored. There is also a need of studies that have focus on the person's own experiences of balance and the balance tested.
In this observational study we aim to examine the psychometric properties of the Mini-BESTest, in individuals with chronic pain. Further we aim to explore individual subjective beliefs and experiences about own balance and being balance tested.
A convenience selection will be used to include two samples of participants. One sample for the test-retest evaluation, here after called the test-retest part of the study. And one sample for a think aloud interview, here after called the interview part of the study. At baseline the participants will be included to one of the two parts.
Participants in the test-retest part will be assessed with the Mini-BESTest on two occasions, the baseline and the re-test within approximately 2 weeks. The inclusion to the test-retest sample will continue until at least 50 individuals with no subjective experience of improvement or deterioration in balance status between the first and second occasions, according to the self-report measure the Patient global impression of change (PGIC), are included. This sampling is done in purpose to calculate test-retest reliability in individuals without subjective change in balance between the two occasions.
To the interview part, approximately ten to twenty individuals will be included for concurrent think aloud, i.e., think aloud during balance testing with the Mini-BESTest, and recurrent think aloud, i.e., an interview after the balance assessment. The interviews will cover questions about the participants experience of the testing with the Mini-BESTest and their balance.
Data will be collected by use of digitized questionnaires, physical performance tests, a structured interview and data from medical records.
Statistical tests will be used to evaluate test-retest reliability and internal consistency. The interviews will be analyzed using thematic analysis.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Pernilla Åsenlöf, Professor
- Phone Number: +46704562831
- Email: pernilla.aselof@uu.se
Study Locations
-
-
-
Uppsala, Sweden, 751 24
- Recruiting
- Uppsala University and University Hospital
-
Contact:
- Pernilla Åsenlöf
- Phone Number: +4618-471 47 68
- Email: pernilla.asenlof@uu.se
-
Principal Investigator:
- Pernilla Åsenlöf, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 years or older
- pain duration of 3 months or more
- a visit for investigation or treatment at the pain clinic
Exclusion Criteria:
- receiving acute care related to active cancer treatment
- receiving palliative care
- having cognitive impairments
- illiterate in the Swedish language
- wheelchair users or bed-bound
- current participating in any of the rehabilitation programs at the pain clinic
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Mini Balance Evaluation Systems Test (Mini-BESTest)
Time Frame: Baseline, 2 weeks
|
Self-report, Swedish version.
Dynamic balance is measured with 14 items ranging from 0 = 'unable or requiring help to perform' to 2 = 'normal'.
All items are summed up to a total score which ranges from 0 to 28, with higher scores reflecting better balance.
|
Baseline, 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numerical Rating Scale (NRS)
Time Frame: Baseline, 2 weeks
|
Self-report, oral question.
Current pain intensity is measured with a scale that ranges from 0-10, where 0 = 'no pain' and 10 = 'pain as bad as can be'.
|
Baseline, 2 weeks
|
Fall frequency
Time Frame: Baseline, 2 weeks
|
Self-report, question about fall frequencies over the last previous year and the last three weeks.
|
Baseline, 2 weeks
|
Activities-Specific Balance Confidence (ABC) scale
Time Frame: Baseline, 2 weeks
|
Self-report, Swedish version.
Balance confidence is measured with 16 items ranging from 0 = 'No confidence' to 100 = 'Full confidence'.
All items are summed up to a total score, which ranges from 0 to 100, with higher scores reflecting higher balance confidence while doing activities.
|
Baseline, 2 weeks
|
Falls Efficacy Scale - international (FES-I)
Time Frame: Baseline, 2 weeks
|
Self-report, Swedish version.
Fear of falling is measured with 16 items ranging from 1 = 'Not at all concerned' to 4 = 'Very concerned'.
All items are summed up to a total score, which ranges from 16 to 64, with higher scores reflecting more concerns about falling.
|
Baseline, 2 weeks
|
Numerical Rating Scales (NRS)
Time Frame: Baseline
|
Self-report.
Pain severity is measured with four scales where worst, least, average and current pain during the past week are scored.
Each scale ranges from 0-10, where 0 = 'no pain' and 10 = 'pain as bad as can be'.
|
Baseline
|
The Pain Disability Index (PDI)
Time Frame: Baseline
|
Self-report, Swedish version.
Pain-related disability is measured with 7 items measuring family/home responsibilities, recreation, social activity, occupation, sexual behavior, self-care and life support activity.
Every item ranges from 0 = 'No disability' to 10 = 'Worst disability'.
All seven items are summed up in a total score, which ranges from 0 to 70, with higher scores reflecting higher interference of pain with daily activities.
|
Baseline
|
2-item Pain Self-Efficacy Questionnaire (PSEQ-2)
Time Frame: Baseline
|
Self-report, Swedish version.
Pain self-efficacy is measured with 2 items ranging from 0 = 'Not at all confident' to 6 = ' Completely confident', with a higher combined scores indicating stronger self-efficacy beliefs.
|
Baseline
|
11-item Tampa Scale for Kinesiophobia (TSK-11)
Time Frame: Baseline
|
Self-report, Swedish version.
Fear of movement and reinjury is measured by 11 items ranging from 1 = 'Does not agree at al' to 4 = 'totally agree).
A total score is calculated ranging from 11 to 44 where higher scores indicates higher fear of movement.
|
Baseline
|
The Public Health Agency of Sweden' questions about physical activity
Time Frame: Baseline
|
Self-report.
Minutes of physical activity on low intensity and moderate intensity is measured with two ordinal scales.
|
Baseline
|
Question about sedentary from the Swedish National Board of Health and Welfare
Time Frame: Baseline
|
Self-report.
Hours of sedentary behavior measured on an ordinal scale.
|
Baseline
|
The Time Line Follow-Back (TLFB) Structured interview
Time Frame: Baseline
|
Patterns of opioid use (type of opioid, dose, and duration) will be measured using a structured interview, calendar format, using 4 weeks intervals starting with the most recent complete week, week 1, working backward one week at time recording days of use for each opioid.
|
Baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient global impression of change (PGIC)
Time Frame: 2 weeks
|
Self-report.
The measure reflects participant's beliefs about if there balance has changed between baseline and the re-test of Mini-BESTest.
The participant indicates whether he/she feels that his/her balance has changed since the previous session of the study on a 7-point scale, 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', 'very much worse'.
|
2 weeks
|
Change in medication
Time Frame: 2 weeks
|
Self-report questions on change in medication between baseline and the re-test of the Mini-BESTest.
The participant indicates whether the type of medication or dose has changed since the previous study visit, the name of the changes medicine, and whether the medicine has been 'added' or 'removed', as well as if the dose has 'increased', 'decreased' or if the participant 'doesn't know'.
|
2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pernilla Åsenlöf, Professor, Uppsala University, Sweden
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-04206-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Non-Cancer Pain
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationRecruitingChronic Non-Cancer PainDenmark
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationNot yet recruitingChronic Non-Cancer Pain
-
University of California, Los AngelesUnknownNon-Cancer Chronic PainUnited States
-
Cosima LocherBrown University; University of BaselNot yet recruiting
-
University of WashingtonNational Institute on Drug Abuse (NIDA)Completed
-
Janssen PharmaceuticaWithdrawnModerate to Severe Chronic Non-cancer Pain
-
Icahn School of Medicine at Mount SinaiEndo PharmaceuticalsUnknownNeuropathic Pain | Non-cancer Pain | Chronic Nociceptive PainUnited States
-
DurectCompletedChronic, Non Malignant PainUnited States
-
Centre Hospitalier Universitaire de NīmesWithdrawn
-
Norwegian University of Science and TechnologyCompletedNon-malignant Chronic Pain